$11.20
+2.0%AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Chief Executive Officer, President & Director
Compensation
$1,606,754
Executive Vice President & Chief Financial Officer
Compensation
$764,270
Senior Vice President & GM of Cardiovascular and International
Compensation
$706,927
Senior Vice President & GM of Oncology and Interventional Devices
Compensation
$592,757
Senior Vice President of Business Development & Strategy
Senior Vice President of Human Resources
Senior Vice President of Information Technology
Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain
Compensation
$625,367
Senior Vice President of Scientific & Clinical Affairs
Vice President of Communications
During the last 12 months, insiders have purchased $240K and sold $71K worth of ANGO shares, resulting in $168K of net buying activity.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
20.9K
239.53K
0
0.00
+240K
+$240K
0
0.00
8.2K
71.32K
-71K
-$71K
Weiss Lawrence T
Officer: Svp, Chief Legal Officer
$118K
Clemmer James C
Director, Officer: President And Ceo
$112K
Trowbridge Stephen A
Officer: Evp And Cfo
$10K
Trowbridge Stephen A
Officer: Evp And Cfo
$35K
Piccinini Laura
Officer: Svp International
$23K
Nighan Warren Jr
Officer: Svp Quality And Regulatory
$11K
Clemmer James C
Director, Officer: President And Ceo
$3K
Strong bullish signal with $168K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs sellingโone of the strongest possible insider signals.
4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
ANGO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | September 25, 2025 | May 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | September 26, 2024 | May 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | September 28, 2023 | May 31, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | September 22, 2022 | May 31, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | September 22, 2021 | May 31, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | September 03, 2020 | May 31, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | September 05, 2019 | May 31, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | August 30, 2018 | May 31, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | September 07, 2017 | October 17, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | September 15, 2016 | October 25, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.